Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company, is set to announce topline results from its Phase 2 OVATION 2 Study on July 30, 2024, at 8:00 a.m. Eastern time. The study focuses on IMNN-001, the company's DNA-mediated immunotherapy for advanced ovarian cancer. IMNN-001 is an interleukin-12 (IL-12) immunotherapy based on IMUNON's TheraPlas™ technology.
Following the announcement, IMUNON will host an investment community conference call at 8:30 a.m. Eastern time to discuss the results and answer questions. Interested parties can participate by dialing 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll). A live webcast and replay of the call will be available, with the replay accessible until August 13, 2024.
IMUNON has announced the database lock for its Phase 2 OVATION 2 Study, which evaluates IMNN-001 in advanced ovarian cancer. The study, involving 110 patients, is assessing the safety, efficacy, and biological activity of IMNN-001 combined with neoadjuvant chemotherapy (NACT). The primary endpoint is Progression-Free Survival (PFS) and secondary endpoints include Overall Survival (OS). The independent statisticians have received the raw data and will analyze it per the Statistical Analysis Plan. IMUNON expects to release topline results by the end of July 2024. This study will guide the design of a planned Phase 3 trial.
IMUNON (NASDAQ: IMNN) has initiated the Phase 1 clinical trial for its IMNN-101 vaccine, a seasonal COVID-19 vaccine developed using its proprietary PlaCCine® DNA platform. The trial aims to evaluate the safety, tolerability, and immune response of the vaccine in 24 healthy volunteers, divided into three dosage groups. The study follows FDA guidelines to combat the SARS-CoV-2 Omicron XBB1.5 variant. IMUNON's preclinical data show promising results, with over 95% immunogenicity and stability at various temperatures. Topline data is expected by year-end 2024.
IMUNON (NASDAQ: IMNN) announced that an abstract detailing a Phase 2 study involving IMNN-001 combined with bevacizumab (Avastin) and neoadjuvant chemotherapy for advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The presentation will occur on June 3, 2024, during the Gynecologic Cancer session at the event in Chicago, which runs from May 31 to June 4.
Lead investigator Dr. Amir A Jazaeri from The University of Texas MD Anderson Cancer Center will present the study, which aims to evaluate the effect of this combination therapy in newly diagnosed patients. The study is actively recruiting participants in the U.S. and is substantially funded by Break Through Cancer.
According to Dr. Sebastien Hazard, IMUNON’s Chief Medical Officer, the synergy observed between IMNN-001 and bevacizumab in pre-clinical experiments is promising, and the company aims to complete enrollment quickly to address this critical clinical question.
IMUNON, Inc. (NASDAQ: IMNN) announces the activation of the first site for its Phase 1 study with IMNN-101, a seasonal Covid-19 vaccine, utilizing its proprietary PlaCCine platform. The study aims to evaluate safety, tolerability, and immune response in healthy adults. Topline results are expected by year-end. IMNN-101 is designed to protect against the SARS-CoV-2 Omicron XBB1.5 variant, with potential advantages over mRNA vaccines in terms of immune protection and vaccine stability.
IMUNON, Inc. (NASDAQ: IMNN) reported financial results for Q1 2024, highlighting clinical development programs with promising results for IMNN-001 immunotherapy and PlaCCine modality. The company also appointed Dr. Stacy Lindborg as President and CEO. Recent developments include positive data in advanced ovarian cancer studies and progress in developing a seasonal COVID-19 booster vaccine. IMUNON received non-dilutive funding and reported a net loss of $4.9 million for Q1 2024.
IMUNON, Inc. (NASDAQ: IMNN) appointed Dr. Stacy R. Lindborg as President and CEO, bringing extensive experience in drug development. Dr. Lindborg takes over at a critical time with key clinical milestones approaching. IMNN-001 results in advanced ovarian cancer expected mid-summer, while Phase 1 data for IMNN-101 in seasonal COVID-19 are anticipated by year-end.
IMUNON, Inc. (NASDAQ: IMNN) will host a conference call on May 13, 2024, to discuss financial results for the first quarter of 2024. The company will provide updates on its clinical development programs, including IMNN-001 for ovarian cancer treatment and the PlaCCine modality for next-generation vaccines.
Summary not available.
Summary not available.